ADC Therapeutics SA (ADCT)
4.125
+0.04
(+0.86%)
USD |
NYSE |
May 17, 16:00
4.125
0.00 (0.00%)
After-Hours: 16:54
ADC Therapeutics Cash from Financing (Quarterly): 0.356M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.356M |
| December 31, 2023 | 1.639M |
| September 30, 2023 | -2.307M |
| June 30, 2023 | 74.12M |
| March 31, 2023 | 0.425M |
| December 31, 2022 | -2.752M |
| September 30, 2022 | 2.365M |
| June 30, 2022 | -0.252M |
| March 31, 2022 | -0.258M |
| Date | Value |
|---|---|
| December 31, 2021 | -1.218M |
| September 30, 2021 | 219.30M |
| June 30, 2021 | 49.60M |
| March 31, 2021 | -0.297M |
| December 31, 2020 | -2.871M |
| September 30, 2020 | 191.28M |
| June 30, 2020 | 306.83M |
| March 31, 2020 | -0.278M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.871M
Minimum
Dec 2020
306.83M
Maximum
Jun 2020
49.16M
Average
0.356M
Median
Mar 2024
Cash from Financing (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Novartis AG | -5.164B |
| AC Immune SA | -0.7872M |
| CRISPR Therapeutics AG | 305.93M |
| Addex Therapeutics Ltd | -0.1643M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -44.10M |
| Cash from Investing (Quarterly) | -0.531M |
| Free Cash Flow | -150.12M |
| Free Cash Flow Per Share (Quarterly) | -0.5406 |
| Free Cash Flow to Equity (Quarterly) | -45.13M |
| Free Cash Flow to Firm (Quarterly) | -35.04M |
| Free Cash Flow Yield | -44.30% |